New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:06 EDTARNAArena Pharmaceuticals initiates Phase 1b clinical trial of APD334
Arena Pharmaceuticals announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers.
News For ARNA From The Last 14 Days
Check below for free stories on ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
12:42 EDTARNAOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTARNAArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTARNAOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 9, 2014
12:46 EDTARNANovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
September 2, 2014
08:18 EDTARNAArena Pharmaceuticals' APD811 granted orphan drug status
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use